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Antigangliosides antibodies were observed in neoplastic
diseases, bacterial and viral infections, autoimmune dis-
eases and neurological disorders. Objective: assessment
of antigangliosides antibodies anti -GM1, -GM2, -GM3,
-GD1a, -GD1b, -GT1b, -GQ1b of IgG type in asympto-
matic HIV patients.
The study was based on the prospective analysis of
32 patients with asymptomatic HIV infection, with no
retroviral treatment, without altered neurological status
associated with the disease and 48 healthy subjects.
Antigangliosides antibodies were determined by
immunoblot method, using Euroline kits.
In healthy subjects, antigangliosides antibodies of IgG
type against all the mentioned gangliosides were negative.
In patients with HIV infection, antigangliosides anti-
bodies of IgG type had the following frequency: 6.2%
anti-GM1, 15.7% anti-GM2, 12.5% anti-GM3, 18.7%
anti-GD1a, 6.2% anti-GD1b, 9.4% anti-GT1b, 18.7%
anti-GQ1b.
The statistical analysis showed a significant difference
between anti-GM2, anti-GD1a and anti-GQ1b status in
HIV group compared with the control group.
The authors considered that gangliosides expressed on
the membrane of HIV infected cells induced antiganglio-
sides antibodies’ synthesis. Antigangliosides antibodies’
presence seems to be a primary immunological event in
HIV infection and might play a physiopathological role in
the studied viral infection.
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